CompletedPhase 2NCT01164228
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Studying Clear cell papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Principal Investigator
- Naomi S. Balzer-Haas, MDAbramson Cancer Center at Penn Medicine
- Intervention
- Gemcitabine(drug)
- Enrollment
- 87 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2021
Study locations (30)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Stanford Cancer Center, Stanford, California, United States
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States
- St. Joseph Medical Center, Bloomington, Illinois, United States
- Graham Hospital, Canton, Illinois, United States
- Memorial Hospital, Carthage, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
- Hematology and Oncology Associates, Chicago, Illinois, United States
- Eureka Community Hospital, Eureka, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01164228 on ClinicalTrials.govOther trials for Clear cell papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05665361Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)National Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05287945Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell CarcinomaOncorena AB
- RECRUITINGPHASE1NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center
See all trials for Clear cell papillary renal cell carcinoma →